



EndoCeutics acquires a manufacturing plant in Mont-Saint-Hilaire, Quebec, Canada

Quebec City, Jan. 16, 2017 – EndoCeutics Inc., a private Quebec City based biopharma company, today announced that it has entered into a partnership, including the acquisition of a manufacturing plant located at 597 Laurier Blvd, Mont-Saint-Hilaire, Quebec J3H 6C4 with Adare Pharmaceuticals, a private global specialty pharmaceutical company. The transaction includes the manufacturing plant with 34 employees who will be transferred to EndoCeutics Pharma (MSH) Inc., a new wholly owned subsidiary of EndoCeutics Inc.

On November 16, 2016, Intrarosa™, a product of EndoCeutics Inc., received FDA approval, and on January 11, 2017, EndoCeutics Inc announced that it has entered into a long-term \$85 million senior credit facility with CRG LP, a healthcare-focused investment firm.

“We are very pleased with the transaction which gives us access to a very efficient FDA-approved facility as well as a highly knowledgeable and professional team,” said Dr. Fernand Labrie, Founder and CEO of EndoCeutics Inc. “The facility in Mont-Saint-Hilaire and its talented employees will enable us to rapidly support our manufacturing needs for the growth of the Intrarosa™ product that provides a safe, effective and superior alternative to existing estrogen-based therapies for patients with vulvovaginal atrophy or the Genitourinary Syndrome of Menopause.”

EndoCeutics estimates that 32 million women suffer from vulvar and vaginal atrophy in the U.S. alone but only approximately one million are treated through prescription products since the majority of these patients fear the side effects of estrogens. EndoCeutics Inc is engaged in active discussions with pharma companies to sell Intrarosa™ in the U.S., Europe, Canada and the rest of the world.

About Endoceutics

Endoceutics is a private pharmaceutical company operating in the field of women's health and hormone-sensitive cancer prevention and treatment. Following approval by the FDA of Intrarosa™ in November 2016, for the treatment of dyspareunia, a symptom of vulvovaginal atrophy due to menopause, Endoceutics focuses on developing non estrogen-based therapies for sexual dysfunction and the other symptoms of menopause, , including hot flushes, osteoporosis, muscle loss and type 2 diabetes. Hormonal therapies for breast, uterine and prostate cancer, male hypogonadism as well as endometriosis are also under development. Endoceutics has five Phase III product candidates addressing large market opportunities and two Phase I/II product candidates. Endoceutics has exclusive worldwide rights to patents, patent applications, technology and know-how related to all its products.

Contact for Endoceutics:

info@endoceutics.com

Tel (418) 653-0033